The World Health Organization (WHO) on Thursday announced its support for weight-loss drugs in adults globally. The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in ...

The treatments, which include medications like semaglutide, liraglutide and exenatide, have been linked to a slightly reduced dementia risk before, but this was based on observational studies ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid. By Margot Sanger ...

Obesity rates have been increasing in the US for decades, but in 2023 they fell – at least in part because of the burgeoning popularity of the “miracle drug” semaglutide. Approved for ...

As experience with these novel antihyperglycemic drugs increases, future studies with longer follow-up periods should be conducted to corroborate our findings. Patients were followed from cohort ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

Drugmakers raised the list prices on 575 name-brand drugs in just the first two days of the new year, according to drug price research firm 46brooklyn. Drugs for diabetes, HIV, cancer saw price ...

2 Several deprescribing guidelines are available to guide clinical decision-making: ‘deprescribing.org’ provides guidance on a variety of medications including antihyperglycemic and antipsychotic ...

HF as an important outcome in patients with type 2 diabetes mellitus seems to be heterogeneously modulated by antihyperglycemic medications, as evidenced by results from cardiovascular outcome trials ...

This study examined the use of antihyperglycemic medications after chronic kidney disease (CKD) onset in patients with type 2 diabetes (T2D) in the US using electronic health records data.

To be eligible for the CATALYST trial, patients had to have an A1c of 7.5-11.5%, be taking three or more antihyperglycemic drugs, taking insulin plus another antihyperglycemic, taking two or more ...